How Patent Expiration Lowers Bedaquiline's Price
Bedaquiline (Sirturo), Janssen's drug for multidrug-resistant tuberculosis, faces patent expiration around 2026 in the US, with some pediatric exclusivity extending to 2027.[1] This shift ends Janssen's monopoly, allowing generic entry, which typically cuts prices by 50-90% through competition, as seen with other TB drugs like rifampicin.[2]
When Do Bedaquiline's Key Patents Expire?
US Patent 7,851,630 (core composition) expires December 29, 2026. Related patents on formulations and methods cover until 2033, but challenges from generics like Mylan could accelerate access.[1] In India, patents expired earlier (2018), enabling local production at far lower costs.
| Patent | Expiration | Status |
|--------|------------|--------|
| US 7,851,630 (compound) | Dec 2026 | Active, challenged |
| US 8,420,676 (formulation) | 2028 | Active |
| Pediatric exclusivity | +6 months (2027) | Delays generics slightly |
Check DrugPatentWatch.com for litigation updates.[1]
Why Do Generics Slash Prices After Expiry?
Without patents, multiple manufacturers produce identical versions, driving bids down in public tenders. Bedaquiline's current US list price exceeds $30,000 per course; post-2026 generics could drop it below $1,000, mirroring delamanid's price fall in low-income markets.[3] Global Fund negotiations already secured $400/course deals, hinting at post-patent norms.
What Challenges Delay Generic Entry?
Evergreening patents (new formulations) and data exclusivity block FDA approval until 2027-2030. Ongoing Paragraph IV lawsuits from Lupin and others test validity; wins for challengers speed market entry by 2-3 years.[1] In Europe, EMA expiry aligns with US, but compulsory licensing in TB-endemic countries bypasses this.
How Have Prices Changed in Patent-Free Markets?
India's generic bedaquiline sells for $300-500/course versus Janssen's $2,900 negotiated price elsewhere.[4] South Africa's voluntary licensing cut costs 40%; full expiry could halve that further. Patients in high-burden areas report 70% savings post-local production.
What Risks or Limits Remain Post-Expiry?
Supply shortages from quality issues plagued early Indian generics, raising resistance fears.[5] Prices may not plummet in wealthy markets due to brand loyalty or new Janssen line extensions. Biosimilar-like standards for small molecules ensure safety but slow rollout.
Sources
[1]: DrugPatentWatch.com - Sirturo Patents
[2]: WHO TB Drug Pricing Report 2023
[3]: MSF Access Campaign - Bedaquiline Report
[4]: TB Alliance Pricing Data
[5]: Lancet Infectious Diseases - Generic Quality Study 2022